Preparation, characterization, in vivo and in vitro studies of arsenic trioxide Mg-Fe ferrite magnetic nanoparticles

Acta Pharmacologica Sinica

Volumn 30, Issue 12, 2009, Pages 1688-1693

  Yang, Guo Fu ^a   Li, Xiang Hui ^b   Zhao, Zhe ^a   Wang, Wen Bo ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

As2O3; Magnetic nanoparticle; Mg Fe ferrite; PLGA; Targeting

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ARSENIC TRIOXIDE; GLYCOLIC ACID DERIVATIVE; IRON DERIVATIVE; MAGNESIUM DERIVATIVE; MAGNESIUM IRON FERRITE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG LIVER LEVEL; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; MAGNETIC FIELD; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; OSTEOSARCOMA CELL; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPE; SPECTROFLUOROMETRY; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ARSENICALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG CARRIERS; FERRIC COMPOUNDS; GLYCOLATES; IRON; KIDNEY; LIVER; MAGNESIUM; MAGNETICS; METAL NANOPARTICLES; MICE; OXIDES;

EID: 74949097982     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.158     Document Type: Article

References (21)

1. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999; 59: 6033-6037
2. Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006; 17: 131-134
3. Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD. Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide. Oncologist 2002; 7: 1-13.
4. Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil Trans R Soc B 2007; 362: 959-971
5. Zhu J, Chen Z, Lallemand-Breitenbach V, de Thé H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002; 2: 1-9.
6. Gielen M, Tiekink ER. Metallotherapeutic drugs and metal-based diagnostic agents. Wiley; 2005. p 298.
7. Griffin RG, Williams BW, Park HJ, Song CW. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy. Int J Radiat Oncol Biol Phys 2005; 61: 1516-1522
8. Zhou J, Meng R, Sui X, Meng L, Jia J, Yang B. Effects of administration styles of arsenic trioxide on intracellular arsenic concentration, cell differentiation and apoptosis. Haematologica 2005; 90: 1277-1279
9. Tun-Kyi A, Qin JZ, Oberholzer PA, Navarini AA, Hassel JC, Dummer R, et al. Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. Ann Oncol 2008; 19: 1488-1494
10. Catarina PR, Ronald JN, António J R, Francisco V. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006; 2: 8-21.
11. Du L, Chen JZ, Qi YT, Li D, Yuan CG, Lin MC, et al. Preparation and biomedical application of a non-polymer coated superparamagnetic nanoparticle. Int J Nanomed 2007; 2: 805-812
12. Sunho P, Kimberly HS. Evaluation of hydrodynamic size and zetapotential of surface-modified au nanoparticle-dna conjugates via ferguson analysis. J Phys Chem 2008; 112: 7611-7616
13. Liu WY. Pharmaceutical analysis. Beijing: People's Medical Publishing House; 2007. 5th edition: p 287-336.
14. Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Carlos Palomino J. Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtitre assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2005; 55: 500-505
15. Chou WC, Dang CV. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol 2005; 12: 1-6.
16. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-3903
17. Chun W, Phuong-Truc P. Polymers for viral gene delivery. Expert Opin Drug Deliv 2008; 5: 385-401.
18. Stevanovi M, Uskokovi D. Poly(lactide-co-glycolide)-based micro and nanoparticles for the controlled drug delivery of vitamins. Curr Nanosci 2009; 5: 1-15.
19. Chen ZP, Zhang Y, Xu K, Xu RZ, Liu JW, Gu N. Stability of hydrophilic magnetic nanoparticles under biologically relevant conditions. J Nanosci Nanotechnol 2008; 8: 6260-6265
20. Yue PF, Yuan HL, Yang M, You RH, Cong LB, Zhu J, et al. Preparation, characterization, and pharmacokinetic evaluation of puerarin submicron emulsion. PDA J Pharm Sci Technol 2008; 62: 32-45.
21. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechaninstic study of enhanced doxorubicin uptake and potention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticles system. J Pharmacol Exp Ther 2006; 317: 1372-1381